Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Melanoma

CheckMate 067—frontline nivolumab improves PFS alone or in combination with ipilimumab

Nature Reviews Clinical Oncology volume 12, page 435 (2015)Cite this article

Subjects

In the era of immunotherapy breakthroughs, the results of the CheckMate 067 trial crown PD-1 inhibitors as the new standard of care for patients with metastatic melanoma, a disease with a very dismal prognosis.

The field of melanoma has witnessed incredible progress in the past 5 years, owing to the approval of agents targeting BRAF mutated disease and the immune checkpoint regulators cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Both CTLA-4 and PD-1-blocking antibodies—ipilimumab and nivolumab, respectively—have demonstrated improved survival in patients with melanoma; preclinical and early stage studies also indicate a synergistic effect of this combination. Building on these findings, the group of researchers led by Jedd Wolchok conducted a double-blind phase III trial, randomizing 945 previously untreated patients with unresectable stage III or IV melanoma to receive nivolumab alone, ipilimumab alone or a combination of nivolumab plus ipilimumab. Treatments were administered until disease progression or unacceptable toxicity; co-primary end points were progression-free survival (PFS) and overall survival.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 10.1056/NEJMoa1504030

Download references

Authors
  1. Alessia Errico
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Errico, A. CheckMate 067—frontline nivolumab improves PFS alone or in combination with ipilimumab. Nat Rev Clin Oncol 12, 435 (2015). https://doi.org/10.1038/nrclinonc.2015.112

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.112

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing